氮氧化钛生物有效性支架与雷帕霉素药物洗脱支架临床应用的比较  

Comparison between titanium nitric oxide biological active stent and sirolimus-eluting stent in clinical practice

作　　者：张孝忠[1] 张晋[1] 张军[1] 王红[1] 原新茹[1] 

机构地区：[1]解放军军事医学科学院307医院心脏内科,北京100071

出　　处：《心脏杂志》2010年第3期393-395,400,共4页Chinese Heart Journal

摘　　要：目的：对比氮氧化钛生物有效性支架（Titan2-BAS）与雷帕霉素药物洗脱支架（sirolimus—eluting stent，SES）在冠状动脉血运重建方面的临床疗效。方法：冠心病患者141例，根据植入的支架不同分为A组（Titan2-BAS）87例，B组（SES）54例，A组病变内径（3．1±0．4）mm，长度（24±3）mm，B组病变内径（3．0±0．5）mm，长度（22±4）mm，两组无显著差异。均采用经桡动脉或尺动脉途径冠脉血运重建。A组阿司匹林与氯吡格雷治疗1～3月，B组至少12月。计算A，B两组支架病变的通过率、早期支架内血栓发生率及随访MACE发生率（指死亡、急性心肌梗死、靶血管重建等）。结果：A组146处〉75％狭窄病变共植入Titan2-BAS168枚，1枚支架未能通过病变（RCA），通过率99．3％；B组86处病变共植入SES94枚，通过率100％，两组无显著差异。随访1～17（平均5．8）月。两组均无死亡病例；A组无急、晚期血栓。B组1例术后2d出现支架内血栓；A组1例术后3月行靶血管重建，8组无靶血管重建；两组MACE发生率无显著差异。结论：Titan2-BAS与SES在冠脉血运重建方面的近期及远期疗效相近，Titan2不增加MACE发生率。AIM： To compare the clinical efficacy of titanium nitric oxide biologically active stents （Titan2- BAS） and sirolimus-eluting stents （SES） in coronary revascularization. METHODS： One hundred and forty one patients with coronary artery disease were enrolled. Eighty seven patients were enrolled in group A treated with titanium nitric oxide biological active stents, whereas the other 54 patients were enrolled in group B treated with sirolimus-eluting stents. The reference vessel diameter was （ 3.1 ± 0. 4 ） mm and lesion length was （24 ± 3 ） mm in group A, whereas diameters and length were （3.0 ± 0.5） mm and （22 ± 4） mm long, respectively, in group B with no significant difference between groups. All stents were implanted through either radial or ulnar artery approach. Patients in group A were given aspirin and clopidogrel for 1 to 3 months, whereas patients in group B used these for at least 12 months. The stent delivery success rate, incidence of early in-stent thrombosis and MACE （death, acute myocardial infarction, and target vessel revascularization） were analyzed in both groups during follow-up. RESULTS： In group A, 168 Titan2-BAS were implanted in 147 lesions with stenosis 〉75%. One stent failed to cross the lesion, the delivery success rate being 99. 3%. In group B, 94 units of SES were implanted in 86 lesions, the delivery success rate being 100%. No significant difference was observed between groups. Follow-up period ranged from 1 to 17 months, with an average of 5.8 months. No deaths were found in both groups. There was no acute or late in-stent thrombosis in group A but one patient in group B suffered from in-stent thrombosis 2 days after the procedure. One patient underwent revascularization 3 months after the procedure in group A and no revascularizations were done in group B. No significant difference on MACE was found between groups. CONCLUSION： Our results suggest that Titan2-BAS is as good as SES in short- and long-term efficacy in coronary revascularization

关 键 词：冠脉血运重建 氮氧化钛生物有效性支架 雷帕霉素药物洗脱支架 

分 类 号：R541.405[医药卫生—心血管疾病]